IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

On April 3, 2026, IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in innovative T cell therapies for cancer and autoimmune diseases, announced an inducement grant approved by its Compensation Committee. The Committee granted nonqualified stock options to two new employees, allowing them to purchase an aggregate of 11,800 shares of the Company's common stock. These awards, granted outside of the Company's 2023 Equity Incentive Plan, align with Nasdaq Listing Rule 5635(c)(4) and are instrumental for attracting talent.

The stock options come with a four-year vesting schedule, wherein 25% will vest upon the completion of the first year of employment. The remaining options will vest in 36 equal monthly installments, contingent on the employees’ continued employment. This structured vesting is intended to foster long-term commitment and align the interests of the employees with those of the company and its shareholders.

Founded with a focus on addressing unmet medical needs, IN8bio is developing both ?? T cell and ?? T cell engager (TCE) product candidates. Key programs include INB-100, an allogeneic ?? T cell candidate aimed at helping adult patients with high-risk leukemias undergoing haploidentical stem cell transplants, and INB-200/400, an autologous genetically modified ?? T cell candidate designed for newly diagnosed Glioblastoma (GBM) patients. Additionally, the company is pioneering a novel T cell engager platform, INB-600, which holds promise for various oncology and autoimmune indications.

For further details on IN8bio's innovative developments, interested parties can visit their website at www.IN8bio.com and can reach out to corporate and media contacts for inquiries.

IN8bio, Inc. (Nasdaq: INAB) recently granted nonqualified stock options to two new employees, allowing them to purchase a total of 11,800 shares. This move, authorized under Nasdaq Listing Rule 5635(c)(4), is strategic for attracting talent to a company focused on innovative T cell therapies for cancer and autoimmune diseases. Understanding the implications of such inducement grants helps investors gauge the company’s outlook, employee value propositions, and overall corporate strategy.

Firstly, the decision to issue stock options external to their 2023 Equity Incentive Plan signals a proactive approach to incentivizing critical hires. This could imply that IN8bio is positioning itself for significant growth, as it seeks to attract skilled personnel essential for advancing its therapeutic development pipeline, particularly with promising candidates like INB-100 (targeting high-risk leukemias) and INB-200/400 (focused on glioblastoma).

Moreover, the vesting structure of these options over four years, with an initial one-year cliff, aligns employee incentives with long-term company performance. For investors, this is a positive indicator that employees are motivated to work towards the company’s success, which could translate into improved performance outcomes and potentially higher stock valuations over time.

From a market perspective, investors should consider the broader implications of these grants. Stock options can create additional shares in the future, slightly diluting existing shareholdings; however, if successfully integrated into a high-growth trajectory, this dilution could be acceptable for the enhanced value created.

Overall, as IN8bio continues to innovate in the biopharmaceutical landscape, its commitment to investing in talent will be crucial. Investors should monitor the company’s progress and potential clinical trial results, as these factors will heavily influence market sentiment and stock performance moving forward.